Asia Pacific Fibrotic Diseases Treatment Market
市场规模（十亿美元）
CAGR :
% 
USD
856.12 Million
USD
1,656.29 Million
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 856.12 Million |
 Market Size (Forecast Year) |
USD 1,656.29 Million |
 CAGR |
% |
| Major Markets Players |
亞太纖維化疾病治療市場，依治療（藥物、器官移植、氧氣治療等）、應用（特發性肺纖維化、肝硬化、腎纖維化、皮膚纖維化等）、最終用戶（醫院、專科診所、學術和研究機構等）劃分 - 產業趨勢及預測（至 2032 年）
亞太纖維化疾病治療市場分析
特發性肺纖維化、肝硬化和腎臟纖維化等纖維化疾病的盛行率不斷上升，是纖維化疾病治療市場的重要驅動力。人口老化、生活方式改變以及糖尿病和高血壓等慢性病發病率上升等因素導致這些疾病的發生率上升。隨著受影響人數的增加，對有效治療的需求也日益增加，從而推動了對包括抗纖維化藥物和生物製劑在內的先進療法的需求。醫療保健系統面臨著管理慢性纖維化疾病的越來越大的壓力，這推動了對更有效治療的需求並促進了市場成長。
亞太纖維化疾病治療市場規模
Data Bridge Market Research 分析稱，亞太地區纖維化疾病治療市場規模預計將從 2024 年的 8.5612 億美元增至 2032 年的 16.5629 億美元，在 2025 年至 2032 年的預測期內，複合年增長率為 8.7%。
亞太纖維化疾病治療市場趨勢
“基於生物標誌物的診斷方法日益普及”
基於生物標記的診斷方法在睪丸生殖細胞腫瘤 (TGCT) 中的應用越來越普遍，其中甲胎蛋白 (AFP)、β-人類絨毛膜促性腺激素 (β-hCG) 和乳酸脫氫酶 (LDH) 等生物標記在臨床實踐中發揮著至關重要的作用。這些生物標記使臨床醫生能夠實現早期發現、監測病情進展並根據每位患者的個人特徵制定治療方案。這一趨勢反映了精準醫療的進步，並使 TGCT 的分期和風險分層更加準確。隨著研究不斷發現更多的生物標記物，這些診斷工具的整合正在成為一種標準方法，增強治療方案並改善患者的治療效果。
亞太纖維化疾病治療市場區隔
|
屬性 |
亞太纖維化疾病治療市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
日本、中國、印度、韓國、澳洲、新加坡、泰國、馬來西亞、印尼、菲律賓、越南、台灣、亞太其他地區 |
|
主要市場參與者 |
CH 勃林格父子股份公司（德國）、F. Hoffmann-La Roche Ltd（瑞士）、Teva Pharmaceutical Industries Ltd.（以色列）、Sandoz International GmbH（德國）、Accord Healthcare（英國）、AbbVie Inc.（美國）、Redx Pharma Pic（英國）、Bristol-Myers Squier Squibb Company（美國）、Henat）、Honaa、Haxa）（Honaa）、Squibb Company（美國）。 pic（英國）、Intercept Pharmaceuticals, Inc.（美國） |
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
亞太纖維化疾病治療市場定義
纖維化疾病是一種由於慢性發炎或組織損傷而形成過多纖維結締組織（纖維化）的疾病。這種異常組織積聚會破壞器官的正常功能，通常會影響肺部（肺纖維化）、肝臟（肝纖維化）、心臟、腎臟和皮膚。
纖維化疾病的治療重點在於減緩或阻止纖維化的進展、減少發炎和控制症狀。治療方法可能包括抗纖維化藥物、免疫抑制劑、改變生活方式，以及在嚴重情況下的器官移植等手術選擇。較新的治療方法探索阻斷導致纖維化發展的特定途徑的標靶療法。
亞太纖維化疾病治療市場動態
驅動程式
- 纖維化疾病盛行率上升
特發性肺纖維化、肝硬化和腎臟纖維化等纖維化疾病的盛行率不斷上升，是亞太地區纖維化疾病治療市場的重要驅動力。人口老化、生活方式改變以及糖尿病和高血壓等慢性病發病率上升等因素導致這些疾病的發生率上升。隨著受影響人數的增加，對有效治療的需求也日益增加，從而推動了對包括抗纖維化藥物和生物製劑在內的先進療法的需求。醫療保健系統面臨著管理慢性纖維化疾病的越來越大的壓力，這推動了對更有效治療的需求並促進了市場成長。
例如，
- 2024 年 8 月，根據 ScienceDirect 發表的一篇文章，對來自 21 個國家/地區的約 800 萬名參與者的 46 項研究進行審查，發現晚期肝纖維化的總體患病率為 3.3%，凸顯了其對亞太地區的巨大且日益增長的影響，並存在明顯的地域差異
- 受亞太地區發病率上升的推動，纖維化疾病的盛行率不斷上升，預計將刺激對有效治療的需求，成為亞太地區纖維化疾病治療市場發展的驅動力
- 2023年1月，根據PubMed Central發表的一篇文章，特發性肺纖維化（IPF）的發生率和盛行率在亞太地區呈上升趨勢，不再符合罕見疾病分類。在北美，發生率為每10,000人2.4至2.98人，其中韓國發生率最高，為每10,000人4.51人
纖維化疾病盛行率的上升極大地推動了市場擴張，凸顯了對更好、更容易獲得的治療方案的需求，同時也鼓勵了該領域研究和開發的增加。
- 吸煙人數增加
吸菸是導致特發性肺纖維化 (IPF) 的最重要危險因子之一。此外，最近的研究表明，吸菸可能會對 IPF 患者的生存產生不利影響。吸菸導致特發性肺纖維化 (IPF) 發病的機制尚不清楚。然而，越來越多的證據表明，氧化壓力的增加可能會促進目前或曾經吸煙的 IPF 患者的病情進展。
例如，
- 2023 年 6 月，根據 NCBI 發表的一篇文章，吸菸是特發性肺纖維化 (IPF) 等間質性肺病 (ILD) 的一個關鍵風險因素，研究表明，41% 至 83% 的 IPF 患者有吸煙史，患上 IPF 的風險高出 60%
- 2022年5月，根據美國國家生物技術資訊中心（NCBI）發表的文章，吸菸已被認為是特發性肺纖維化（IPF）發病的重要危險因子。根據文章中的研究，目前吸菸者和以前吸菸者的特發性肺纖維化風險明顯高於從不吸菸者，aHR 分別為 1.66（95% CI 1.61 至 1.72）和 1.42（95% CI 1.37 至 1.48）。目前吸菸者罹患 IPF 的風險高於曾經吸菸者（aHR 1.17，95% CI 1.13 至 1.21）。隨著吸煙強度和吸煙持續時間的增加，患特發性肺纖維化的風險也會增加
因此，香菸煙霧中含有顆粒物以及多種化學物質，包括劇毒的RONS，這會增加體內腫脹，從而導致各種疾病，包括肺纖維化、癌症等，預計這將推動亞太纖維化疾病治療市場的成長
機會
- 研發活動不斷增加
纖維化疾病的盛行率不斷上升以及對更有效治療的需求促使製藥和生物技術公司加強研發投入。這些努力旨在開發創新療法，包括針對纖維化根本原因的新型抗纖維化藥物、生物製劑和基因療法。此外，個人化醫療和診斷技術的進步有望改善治療結果和整體患者護理。隨著研發的進展，新的治療選擇將會出現，從而促進市場成長並改善纖維化疾病的管理。
例如，
- 2021年7月，根據Moez Ghumman等人發表的文章，現有的口服療法吡非尼酮和尼達尼布可能試圖透過減輕症狀和減緩病情進展來改善患者的生活質量，然而這些藥物的長期劑量和全身給藥可能會導致嚴重的副作用。由於缺乏有效的治療選擇，需要進一步研究 IPF 的恢復性療法和額外的安寧療護。基於奈米顆粒的持續藥物輸送策略可用於確保針對特定部位治療和長效治療的靶向輸送，從而提高患者的整體依從性
研發活動的增加為透過促進創新和加強治療策略來加速市場擴張提供了重大機會。
- 藥物研發進展
越來越多有前景的療法，包括新型抗纖維化藥物、生物製劑和基因療法，目前正處於不同的開發階段。這些藥物旨在針對纖維化疾病的根本原因，提供更有效的治療和改善患者預後的潛力，特別是對於特發性肺纖維化、肝硬化和腎臟纖維化等疾病。這些藥物的成功批准和商業化將擴大可用的治療選擇範圍，滿足對更好治療日益增長的需求，並促進市場成長。
例如，
- 2024年9月，根據肺纖維化基金會發表的一篇文章，目前處於纖維化疾病第一期研發階段的藥物包括自體肺球體幹細胞、AZD5055、達沙替尼+槲皮素、表沒食子兒茶素-3-沒食子酸酯、NIP292、ORIN1001、薩拉替尼、西威尼莫昔莫、
- 2022 年 2 月，根據 NCBI 報告，一項於 2021 年 2 月啟動的 I/II 期臨床試驗正在德黑蘭 Taleghani 醫院測試伊馬替尼 (200 毫克/天) 治療晚期肝纖維化 (3-4 級)。該試驗在 24 週內對伊馬替尼與標準治療和安慰劑進行了比較
限制/挑戰
- 藥物和治療費用高昂
由於患有纖維化的患者數量不斷增加以及醫療器材和藥品價格上漲，纖維化疾病的治療費用也越來越高。用於纖維化治療的現代技術設備也在治療費用高、準確性高方面發揮重要作用，為特發性肺纖維化 (IPF) 提供明確的診斷。因此，纖維化疾病的藥物和治療程序的高成本阻礙了市場的成長。
例如，
- 2022年10月，根據PubMed Central發表的一篇文章，特發性肺纖維化的治療選擇有限，目前只有兩種核准的抗纖維化藥物—吡非尼酮和尼達尼布—可用於治療輕度至中度病例。這些藥物價格昂貴，根據國家不同，每人每月費用從 2,000 美元到 14,000 美元不等
- 2022 年 9 月，根據 Alan Katz 等人發表的文章，高壓氧療法每次治療的費用通常在 250 美元至 600 美元之間，具體取決於幾個因素，包括治療次數和服務地點
- 2022年1月，根據BMC Pulmonary Medicine發表的一篇文章報道，吡非尼酮的年標價約為36,070.80美元，而在美國，吡非尼酮和尼達尼布的年費用均超過100,000美元，在比利時，尼達尼布的年標價約為28,910美元。預計藥物和治療的高成本將對亞太纖維化疾病治療市場造成限制，限制獲得這些療法的機會，並給患者和醫療保健系統帶來經濟壓力
纖維化疾病的複雜性與多因素性
纖維化是由多種因素引起的，包括遺傳傾向、環境暴露和潛在的慢性疾病，因此很難確定單一原因或製定一刀切的治療方法。這種複雜性使得開發能夠解決纖維化所涉及的多種機制的有效療法變得複雜。此外，這些疾病具有漸進性，且通常在晚期才會出現症狀，這進一步增加了早期診斷和治療的複雜性，導致幹預延遲。
例如，
- 2023 年 1 月，根據 PubMed Central 發表的一篇文章，在特發性肺纖維化 (IPF) 中，正常肺組織被異常基質積聚所取代，從而損害肺泡功能並導致呼吸衰竭。反覆的微損傷和細胞修復中斷會導致不可逆的肺損傷
纖維化疾病的這種複雜性和多因素性對開發有效的治療方法提出了重大挑戰，影響了亞太地區纖維化疾病治療市場
纖維化疾病的多面性要求高度客製化的治療方法，這對製藥公司開發普遍有效的治療方法和策略來管理這些疾病提出了挑戰。
亞太纖維化疾病治療市場範圍
市場根據處理、應用和最終用戶進行細分。這些細分市場之間的成長將幫助您分析行業中成長微弱的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。
本研究報告將亞太地區纖維化疾病治療市場分為以下幾個部分：
按治療
- 藥物
- 尼達尼布（OFEV）
- 吡非尼酮（ESBRIET）
- 器官移植
- 氧氣療法
- 其他的
按應用
- 特發性肺纖維化
- 肝硬化
- 腎臟纖維化
- 皮膚纖維化
- 其他的
按最終用戶
- 醫院
- 專科診所
- 學術和研究機構
- 其他的
亞太纖維化疾病治療市場區域分析
市場根據處理、應用和最終用戶進行細分。
市場涵蓋的國家包括日本、中國、印度、韓國、澳洲、新加坡、泰國、馬來西亞、印尼、菲律賓、越南、台灣和亞太其他地區。
由於醫療保健投資的增加、對纖維化疾病的認識的提高以及獲得先進醫療療法的機會的改善，日本預計將成為市場上成長最快的國家。該地區人口眾多且老化，加上與纖維化相關的慢性疾病（如糖尿病和肝病）負擔日益加重，進一步推動了對有效治療的需求。
報告的國家部分還提供了影響個別市場因素以及影響市場當前和未來趨勢的國內市場監管變化。下游和上游價值鏈分析、技術趨勢和波特五力分析、案例研究等數據點是用於預測各國市場情景的一些指標。此外，在對國家數據進行預測分析時，還考慮了亞太品牌的存在和可用性，以及由於來自本地和國內品牌的大量或稀缺的競爭而面臨的挑戰、國內關稅和貿易路線的影響。
亞太地區纖維化疾病治療市佔率
市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、亞太地區業務、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用優勢。以上提供的數據點僅與公司對市場的關注有關。
亞太地區纖維化疾病治療市場的領導者有：
- CH 勃林格父子股份公司（德國）
- F. Hoffmann-La Roche Ltd（瑞士）
- 梯瓦製藥工業股份有限公司（以色列）
- Sandoz International GmbH（德國）
- Accord Healthcare（英國）
亞太纖維化疾病治療市場最新發展
- 2024年9月，勃林格殷格翰國際有限公司宣布，FIBRONEER-IPF試驗在第52週達到了FVC改善的主要終點，併計劃向FDA和其他亞太地區主管部門提交用於治療IPF的nerandomilast的新藥申請。這項成功的試驗和即將提交的申請將加強勃林格殷格翰在競爭激烈的特發性肺纖維化（IPF）市場中的地位，並有可能擴大其呼吸系統藥物組合
- 2022 年 11 月，梯瓦製藥工業有限公司 (Teva Pharmaceutical Industries Ltd.) 的美國分公司梯瓦製藥 (Teva Pharmaceuticals) 宣布與領先的臨床管理平台 Rimidi 建立新的合作，旨在優化臨床工作流程、增強患者體驗和實現品質目標。這有助於該公司拓展亞太地區
- 2022 年 3 月，羅氏集團成員基因泰克宣布，III 期 SKYSCRAPER-02 研究未達到無進展生存期這一共同主要終點，該研究評估了在研抗 TIGIT 免疫療法 tiragolumab 聯合 Tecentriq（atezolizumab）和化療（卡鉑和依托苷類）作為廣泛期小細胞 (ES-這有助於該公司拓展亞太地區
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS
5.1 NORTH AMERICA
5.1.1 U.S.
5.1.2 CANADA
5.2 EUROPE
5.2.1 EUROPEAN UNION (EMA - EUROPEAN MEDICINES AGENCY)
5.2.2 GERMANY (FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES - BFARM)
5.2.3 UNITED KINGDOM (MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MHRA)
5.3 ASIA-PACIFIC
5.3.1 JAPAN (PMDA - PHARMACEUTICALS AND MEDICAL DEVICES AGENCY)
5.3.2 CHINA (NMPA - NATIONAL MEDICAL PRODUCTS ADMINISTRATION)
5.3.3 AUSTRALIA (TGA - THERAPEUTIC GOODS ADMINISTRATION)
5.4 LATIN AMERICA
5.4.1 BRAZIL (ANVISA - BRAZILIAN HEALTH REGULATORY AGENCY)
5.4.2 ARGENTINA (ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA - ANMAT)
5.5 MIDDLE EAST AND AFRICA (MEA)
5.5.1 UNITED ARAB EMIRATES (UAE - MINISTRY OF HEALTH AND PREVENTION)
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF FIBROTIC DISEASES
6.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES
6.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES
6.1.4 AWARENESS AND EARLY DIAGNOSIS INITIATIVES
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATION AND TREATMENTS
6.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES
6.3 OPPORTUNITIES
6.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.2 ADVANCEMENTS IN PIPELINE DRUG DEVELOPMENTS
6.3.3 INCREASING STRATEGIC COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.
6.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES,
7 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 MEDICATION, BY TREATMENT
7.2.2 MEDICATION, BY DISTRIBUTION CHANNEL
7.3 ORGAN TRANSPLANT
7.4 OXYGEN THERAPY
7.5 OTHERS
8 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IDIOPATHIC PULMONARY FIBROSIS
8.3 HEPATIC CIRRHOSIS
8.4 RENAL FIBROSIS
8.5 CUTANEOUS FIBROSIS
8.6 OTHERS
9 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 ACADEMIC AND RESEARCH INSTITUTES
9.5 OTHERS
10 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY REGION
10.1 ASIA PACIFIC
11 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 SANDOZ INTERNATIONAL GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 ACCORD HEALTHCARE
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 ABBVIE INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 BRISTOL-MYERS SQUIBB COMPANY.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BIOMX.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 INTERCEPT PHARMACEUTICALS, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 KITHER BIOTECH S.R.L.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 REDX PHARMA PLC.
13.11.1 COMPANY SNAPSHOT
13.11.2 REVENUE ANALYSIS
13.11.3 PRODUCT PORTFOLIO
13.11.4 RECENT DEVELOPMENTS
13.12 VERONA PHARMA PLC
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
表格列表
TABLE 1 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)
TABLE 5 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)
TABLE 6 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 25 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 26 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 30 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 31 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 32 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 33 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 34 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 35 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 36 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 37 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 38 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 39 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 40 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 41 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 45 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 46 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 47 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 48 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 49 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 50 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 51 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 53 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 54 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 55 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 58 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 59 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 60 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 61 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 62 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 64 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 65 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 66 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 67 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 68 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 69 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 70 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 72 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 73 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 74 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 75 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 76 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 78 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 79 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 80 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 81 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 82 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 83 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 84 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 85 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 86 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 87 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 88 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 89 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 90 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 91 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 92 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 93 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 94 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 95 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 96 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 97 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 98 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 99 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 100 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 101 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 102 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 103 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 104 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 105 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 106 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 107 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 108 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 109 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 110 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 111 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 112 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 113 REST OF ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032
FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032
FIGURE 15 MARKET OVERVIEW
FIGURE 16 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 17 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 18 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 19 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024
FIGURE 21 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 22 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)
FIGURE 23 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024
FIGURE 25 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 26 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 27 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 29 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
